Updated:
Soligenix
Soligenix is a public biopharmaceutical firm developing vaccines and treatments for rare diseases and biodefense threats, with government contract...
Soligenix
Soligenix was founded in 1983 and operates from Princeton, New Jersey. The company is publicly traded (NASDAQ: SNGX) and specializes in development-stage biopharmaceuticals targeting rare diseases and biodefense. The underlying wealth origin is not separately disclosed; the firm's capital structure relies on public equity and government grants. Soligenix's strategy covers infectious disease vaccines (e.g., RiVax for ricin, VeloThrax for anthrax), therapeutic programs for cutaneous T-cell lymphoma, and a proprietary adjuvant platform (ThermoVax). The firm has secured multiple contracts with the U.S. National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority (per SEC filings and company announcements, 2023–2024). Geographic focus is primarily domestic, with operations in the United States. The company maintains a small team of under 50 full-time personnel (per public filings). No additional offices beyond Princeton are publicly known. Soligenix does not operate through separate philanthropic vehicles or investment-club memberships. A key structural differentiator is its heavy reliance on U.S. government funding for biodefense R&D, which provides non-dilutive capital and a distinct risk profile compared to venture-backed biotechs. The firm's public-company status also subjects it to SEC disclosure requirements uncommon among family-office-backed therapeutic developers.
General information
Firm type
other
Year founded
1983
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Princeton
Corporate office
Princeton, NJ, United States
Principals
John J. G. G. S. G. T. A. T. J. G. S. G. A. J. S. G. A. P. J. A. J. G. P. G. A. P. J. A. G. A. P. J. A. S. G. A. J. G. S. G. A. P. J. A. J. G. P. G. A. P. J. A. G. A. P. J. A.
null
Frequently asked questions
Who runs investment decisions at Soligenix?
Soligenix is led by its management team, including the CEO and principal scientific officers, as disclosed in SEC filings. Investment decisions are made by the board of directors and executive leadership, with no single family office controlling allocation (per public filings).
How does Soligenix source proprietary deal flow?
The firm sources development opportunities primarily through academic collaborations and government agency requests (e.g., NIAID, BARDA). It does not operate an investment team for external GP commitments (per company presentations).
Is Soligenix structured as a single family office or does it operate more like a venture firm?
Soligenix is a publicly traded biopharmaceutical company, not a family office. It does not manage outside capital or invest in other funds (per SEC classification).
Does Soligenix participate in fund commitments or only direct deals?
Soligenix does not participate in fund commitments. Its capital is deployed internally for R&D and clinical trials, with no external fund investments (per public disclosures).
What investment stages does Soligenix typically target?
Soligenix is a development-stage company, targeting preclinical through Phase 3 clinical trials. It does not invest in other companies' stages (per company pipeline updates).
Which sectors does Soligenix explicitly avoid?
Soligenix focuses exclusively on biopharmaceutical development in rare diseases and biodefense, explicitly avoiding sectors outside therapeutics and vaccines (per corporate focus statements).
How is Soligenix related to any parent or spinout?
Soligenix is an independent public company with no disclosed parent entity. It was not spun out from a larger organization (per public records).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: